These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 21990093)

  • 1. Lenalidomide for aggressive B-cell lymphoma involving the central nervous system?
    Cox MC; Mannino G; Lionetto L; Naso V; Simmaco M; Spiriti MA
    Am J Hematol; 2011 Nov; 86(11):957. PubMed ID: 21990093
    [No Abstract]   [Full Text] [Related]  

  • 2. Lenalidomide, as a single agent, induces complete remission in a refractory mantle cell lymphoma.
    Tempescul A; Ianotto JC; Morel F; Marion V; De Braekeleer M; Berthou C
    Ann Hematol; 2009 Sep; 88(9):921-2. PubMed ID: 19139889
    [No Abstract]   [Full Text] [Related]  

  • 3. Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom.
    Tucker DL; Naylor G; Kruger A; Hamilton MS; Follows G; Rule SA
    Br J Haematol; 2017 Jul; 178(2):327-329. PubMed ID: 27197509
    [No Abstract]   [Full Text] [Related]  

  • 4. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Wiernik PH; Lossos IS; Tuscano JM; Justice G; Vose JM; Cole CE; Lam W; McBride K; Wride K; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Habermann TM
    J Clin Oncol; 2008 Oct; 26(30):4952-7. PubMed ID: 18606983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.
    Habermann TM; Lossos IS; Justice G; Vose JM; Wiernik PH; McBride K; Wride K; Ervin-Haynes A; Takeshita K; Pietronigro D; Zeldis JB; Tuscano JM
    Br J Haematol; 2009 May; 145(3):344-9. PubMed ID: 19245430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors.
    Fine HA; Kim L; Albert PS; Duic JP; Ma H; Zhang W; Tohnya T; Figg WD; Royce C
    Clin Cancer Res; 2007 Dec; 13(23):7101-6. PubMed ID: 18056189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide-induced tumour flare reaction in mantle cell lymphoma.
    Eve HE; Rule SA
    Br J Haematol; 2010 Nov; 151(4):410-2. PubMed ID: 20880113
    [No Abstract]   [Full Text] [Related]  

  • 8. Response of cutaneous lesion of mantle cell lymphoma to lenalidomide.
    Mishchenko E; Attias D; Tadmor T
    Int J Hematol; 2014 Jul; 100(1):1-2. PubMed ID: 24838993
    [No Abstract]   [Full Text] [Related]  

  • 9. Haematological cancers: Lenalidomide--SPRINT to a new standard?
    Hutchinson L
    Nat Rev Clin Oncol; 2016 Apr; 13(4):204. PubMed ID: 26925960
    [No Abstract]   [Full Text] [Related]  

  • 10. Ibrutinib as salvage therapy in mantle cell lymphoma with central nervous system involvement in a pretreated unfit patient.
    Vitagliano O; Trastulli F; Cacace F; Leone S; Memoli M; Scalia G; Notarangelo M; Mainolfi CG; De Renzo A; Pane F
    Leuk Lymphoma; 2018 Jul; 59(7):1734-1737. PubMed ID: 29019439
    [No Abstract]   [Full Text] [Related]  

  • 11. Central nervous system T-cell lymphoma in acquired immunodeficiency syndrome.
    Yotsumoto M; Funato K; Hashimoto Y; Fujimoto H; Fukutake K
    Br J Haematol; 2010 Mar; 148(5):807-8. PubMed ID: 19912221
    [No Abstract]   [Full Text] [Related]  

  • 12. Effective treatment of pomalidomide in central nervous system myelomatosis.
    Mussetti A; Dalto S; Montefusco V
    Leuk Lymphoma; 2013 Apr; 54(4):864-6. PubMed ID: 22880953
    [No Abstract]   [Full Text] [Related]  

  • 13. Mantle cell lymphoma with central nervous system involvement: frequency and clinical features.
    Gill S; Herbert KE; Prince HM; Wolf MM; Wirth A; Ryan G; Carney DA; Ritchie DS; Davies JM; Seymour JF
    Br J Haematol; 2009 Oct; 147(1):83-8. PubMed ID: 19694718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution of lenalidomide into semen of healthy men after multiple oral doses.
    Chen N; Lau H; Choudhury S; Wang X; Assaf M; Laskin OL
    J Clin Pharmacol; 2010 Jul; 50(7):767-74. PubMed ID: 20160158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide for mantle cell lymphoma.
    Skarbnik AP; Goy AH
    Expert Rev Hematol; 2015 Jun; 8(3):257-64. PubMed ID: 25952533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colonic involvement in a patient with mantle cell lymphoma.
    Gaglia A; Foukas P; Polymeros D
    Clin Gastroenterol Hepatol; 2010 Oct; 8(10):e99-100. PubMed ID: 20601143
    [No Abstract]   [Full Text] [Related]  

  • 17. Response to thalidomide in chemotherapy-resistant mantle cell lymphoma: a case report.
    Wilson EA; Jobanputra S; Jackson R; Parker AN; McQuaker IG
    Br J Haematol; 2002 Oct; 119(1):128-30. PubMed ID: 12358916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma.
    Houillier C; Choquet S; Touitou V; Martin-Duverneuil N; Navarro S; Mokhtari K; Soussain C; Hoang-Xuan K
    Neurology; 2015 Jan; 84(3):325-6. PubMed ID: 25527263
    [No Abstract]   [Full Text] [Related]  

  • 19. Primary central nervous system lymphomas (PCNSL): MRI response criteria revised.
    Küker W; Nägele T; Thiel E; Weller M; Herrlinger U
    Neurology; 2005 Oct; 65(7):1129-31. PubMed ID: 16217075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab.
    Martin Mdel P; Cravens PD; Winger R; Kieseier BC; Cepok S; Eagar TN; Zamvil SS; Weber MS; Frohman EM; Kleinschmidt-Demasters BK; Montine TJ; Hemmer B; Marra CM; Stüve O
    Arch Neurol; 2009 Aug; 66(8):1016-20. PubMed ID: 19667224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.